EyeYon Medical Overview

  • Founded
  • 2010
Founded
  • Status
  • Private
  • Employees
  • 19
Employees
  • Latest Deal Type
  • Series C
  • Latest Deal Amount
  • $25M
Latest Deal Amount
  • Investors
  • 12

EyeYon Medical General Information

Description

Developer of an ophthalmic contact lens designed to treat corneal edema. The company's lens is created for therapeutic use to promote corneal healing and relieve corneal pain during the treatment of acute or chronic pathologies and is non-invasive, comfortable, and simple to use, enabling patients to take complete care of their eyes.

Contact Information

Website
www.eye-yon.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Therapeutic Devices
Primary Office
  • 3 Golda Meir Street
  • 6th Floor
  • Nes Ziona 7403648
  • Israel
+972 000-000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

EyeYon Medical Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Later Stage VC (Series C) 15-Mar-2021 $25M 000.00 Completed Generating Revenue
5. Later Stage VC (Series B) 21-Mar-2017 000 000.00 000.00 Completed Generating Revenue
4. Accelerator/Incubator 01-Jan-2016 00.000 Completed Generating Revenue
3. Later Stage VC (Series A) 05-Apr-2015 00.00 00.000 00.000 Completed Startup
2. Early Stage VC 28-Apr-2014 $949K $949K 00.00 Completed Startup
1. Accelerator/Incubator Completed Startup
To view EyeYon Medical’s complete valuation and funding history, request access »

EyeYon Medical Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Preferred B 000,000 00.000000 000.00 000.00 00 000.00 00.000
Preferred A2 00,000 00.000000 000.00 000.00 00 000.00 0.000
Preferred A1 000,000 00.000000 000.00 000.00 00 000.00 00.000
Preferred Seed 2 15,000 $0.010000 $12 $12 1x $12 2.75%
Preferred Seed 1 330,000 $0.010000 $11.56 $11.56 1x $11.56 12.95%
To view EyeYon Medical’s complete cap table history, request access »

EyeYon Medical Patents

EyeYon Medical Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20210369443-A1 Corneal implant injector system Pending 27-May-2020 000000000
US-20200170786-A1 Corneal implant with peripheral skirt Abandoned 02-Dec-2018 0000000000 0
US-20210128359-A1 Treatment to improve adhesive properties of corneal implant Granted 08-Jan-2018 00000000000
EP-3709934-A1 Treatment to improve adhesive properties of corneal implant Pending 08-Jan-2018 00000000000
JP-2021509631-A Measures to improve the adhesive properties of corneal implants Pending 08-Jan-2018 A61F9/00825
To view EyeYon Medical’s complete patent history, request access »

EyeYon Medical Executive Team (6)

Name Title Board Seat Contact Info
Nahum Ferera Co-Founder & Chief Executive Officer
Ofer Daphna MD Co-Founder & Medical Director
Ethan Nash Financial Director
Arie Marcovich MD Co-Founder
Michal Shavit Head of Sales & Marketing
You’re viewing 5 of 6 executive team members. Get the full list »

EyeYon Medical Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

EyeYon Medical Investors (12)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Booth Park Capital PE/Buyout Minority 000 0000 000000 0
Quark Venture Venture Capital Minority 000 0000 000000 0
China Resources Capital Management Corporate Venture Capital Minority 000 0000 000000 0
Diamond Capital (Taiwan) Venture Capital Minority 000 0000 000000 0
Gauss (Roma) Other Minority 000 0000 000000 0
You’re viewing 5 of 12 investors. Get the full list »